Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of ABSK043 + osimertinib in EGFR-mutant advanced non-small cell lung cancer
CTR20262744Phase 2Active
- Sponsor
- Abbisko Therapeutics
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lumipodlin, osimertinib in non-small cell lung cancer (NSCLC), sponsored by Abbisko Therapeutics. Started Sep 2026; status: active.
02
Drugs
lumipodlinosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20262744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262744.